Sun Pharma Q1 Results: Sun Pharma reported a 27% YoY rise in Q1 net profit to Rs 2,895 crore, while revenue grew 10% to Rs 15,300 crore, driven by strong performance in India and its innovative medicines business despite weak US formulations sales. EBITDA rose 3% to Rs 4,418 crore. The company highlighted semaglutide approvals and said the Organon acquisition remains on track for early 2027.
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.